Rapid Micro Biosystems, Inc. (RPID)
Nasdaq · Laboratory Analytical Instruments · Manufacturing · CIK 1380106 · fiscal year ends in Dec
Closing price $0.74 on 30 Oct 2026; 52-week range $0.74 to $4.68.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $35.2M
- Revenue growth
- 16.1%
- Net income, last twelve months
- -$51.2M
- Earnings per share
- -$1.12
- Gross margin
- 5.5%
- Operating margin
- -141.5%
- Net margin
- -145.6%
- Return on equity
- -288.5%
- Market value
- $37.1M
- Cash
- $14.7M
- Debt
- $19.1M
- Debt to equity
- 1.08
- Shares outstanding
- 50.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $33.6M | -$47.4M | -$47.1M | -$1.05 | -$31.9M | 10-K filed 12 Mar 2026 |
| FY2024 | 31 Dec 2024 | $28.1M | -$49.9M | -$46.9M | -$1.08 | -$45.5M | 10-K filed 28 Feb 2025 |
| FY2023 | 31 Dec 2023 | $22.5M | -$56.6M | -$52.5M | -$1.22 | -$46.9M | 10-K filed 1 Mar 2024 |
| FY2022 | 31 Dec 2022 | $17.1M | -$63.2M | -$60.8M | -$1.43 | -$65.3M | 10-K filed 10 Mar 2023 |
| FY2021 | 31 Dec 2021 | $23.2M | -$47.2M | -$73.5M | -$3.94 | -$58.2M | 10-K filed 24 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $8.1M | -$12.9M | -$0.27 |
| Q1 FY2026 | 31 Mar 2026 | $8.0M | -$14.3M | -$0.31 |
| Q4 FY2025 | 31 Dec 2025 | $11.3M | -$12.5M | -$0.28 |
| Q3 FY2025 | 30 Sep 2025 | $7.8M | -$11.5M | -$0.26 |
| Q2 FY2025 | 30 Jun 2025 | $7.3M | -$11.9M | -$0.27 |
| Q1 FY2025 | 31 Mar 2025 | $7.2M | -$11.3M | -$0.26 |
| Q4 FY2024 | 31 Dec 2024 | $8.2M | -$9.7M | -$0.22 |
| Q3 FY2024 | 30 Sep 2024 | $7.6M | -$11.3M | -$0.26 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product | $23.4M | 69.7% |
| Service | $10.2M | 30.3% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $13.4M | 40.0% |
| Switzerland | $6.0M | 17.9% |
| All other countries | $5.8M | 17.2% |
| Germany | $5.8M | 17.2% |
| Japan | $2.6M | 7.7% |
Company events
The newest 8-K filings of 47 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 7 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 28 May 2026 | 8-K | Shareholder vote | 5.07 |
| 19 May 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 13 May 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 12 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 13 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 7 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 12 Aug 2025 | 8-K | Results, Material agreement, New debt, Share sale, Investor update | 1.01, 2.02, 2.03, 3.02, 7.01, 9.01 |
| 17 Jun 2025 | 8-K | Other events | 8.01, 9.01 |
| 23 May 2025 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07 |
| 9 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 131 held.
| Filed | Form | Period |
|---|---|---|
| 7 Aug 2026 | 10-Q | 30 Jun 2026 |
| 7 Aug 2026 | 8-K | 7 Aug 2026 |
| 29 May 2026 | SD | – |
| 28 May 2026 | 8-K | 21 May 2026 |
| 19 May 2026 | 8-K | 18 May 2026 |
| 15 May 2026 | 10-Q | 31 Mar 2026 |
| 13 May 2026 | 8-K | 13 May 2026 |
| 8 Apr 2026 | ARS | 31 Dec 2025 |
| 8 Apr 2026 | DEFA14A | – |
| 8 Apr 2026 | DEF 14A | 21 May 2026 |
| 27 Mar 2026 | 8-K | 23 Mar 2026 |
| 12 Mar 2026 | S-8 | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 11 Mar 2026 | Wilson John J. Addington, CHIEF OPERATING OFFICER | Sale outside a trading plan | 9,603 | $4.32 | $41.5K | 316,762 | 12 Mar 2026 |
| 11 Mar 2026 | Wirtjes Sean M, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 7,480 | $4.32 | $32.3K | 556,194 | 12 Mar 2026 |
| 10 Mar 2026 | Spignesi Robert G. Jr., PRESIDENT AND CEO | Sale outside a trading plan | 17,922 | $4.11 | $73.7K | 1,169,848 | 12 Mar 2026 |
| 20 Feb 2026 | Wilson John J. Addington, CHIEF OPERATING OFFICER | Sale outside a trading plan | 5,403 | $3.92 | $21.2K | 326,365 | 20 Feb 2026 |
| 20 Feb 2026 | Wirtjes Sean M, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 17,254 | $3.92 | $67.7K | 563,674 | 20 Feb 2026 |
| 19 Feb 2026 | Spignesi Robert G. Jr., PRESIDENT AND CEO | Sale outside a trading plan | 38,327 | $3.89 | $148.9K | 1,187,770 | 20 Feb 2026 |
| 9 Feb 2026 | Wilson John J. Addington, CHIEF OPERATING OFFICER | Sale outside a trading plan | 4,610 | $3.78 | $17.4K | 257,768 | 10 Feb 2026 |
| 9 Feb 2026 | Wirtjes Sean M, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 6,027 | $3.78 | $22.8K | 483,928 | 10 Feb 2026 |
| 9 Feb 2026 | Spignesi Robert G. Jr., PRESIDENT AND CEO | Sale outside a trading plan | 12,840 | $3.78 | $48.6K | 962,097 | 10 Feb 2026 |
| 4 Feb 2026 | Longitude Capital Partners Ii, Llc, 10% owner | Sale outside a trading plan | 49,000 | $3.88 | $190.1K | 0 | 6 Feb 2026 |
| 3 Feb 2026 | Longitude Capital Partners Ii, Llc, 10% owner | Sale outside a trading plan | 27,500 | $4.24 | $116.6K | 49,000 | 3 Feb 2026 |
| 2 Feb 2026 | Longitude Capital Partners Ii, Llc, 10% owner | Sale outside a trading plan | 27,500 | $4.25 | $116.8K | 76,500 | 3 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 8 Jul 2026 | Wilson John J. Addington, Former Officer | 10,000 | $17.0K | 8 Jul 2026 |
| 1 Jul 2026 | Wilson John J. Addington, Former Officer | 6,312 | $11.0K | 1 Jul 2026 |
| 22 Jun 2026 | Wilson John J. Addington, Former Officer | 3,688 | $6.5K | 22 Jun 2026 |
| 10 Jun 2026 | Wilson John J. Addington, Former Officer | 5,000 | $9.3K | 10 Jun 2026 |
| 11 Mar 2026 | WIRTJES SEAN M, Officer | 7,480 | $32.3K | 11 Mar 2026 |
| 11 Mar 2026 | Wilson John J. Addington, Officer | 9,603 | $41.5K | 11 Mar 2026 |
| 10 Mar 2026 | Spignesi Robert G. Jr., Officer, Director | 17,922 | $73.7K | 10 Mar 2026 |
| 20 Feb 2026 | Wilson John J. Addington, Officer | 5,403 | $21.2K | 20 Feb 2026 |
| 20 Feb 2026 | WIRTJES SEAN M, Officer | 17,254 | $67.7K | 20 Feb 2026 |
| 19 Feb 2026 | Spignesi Robert G. Jr., Officer, Director | 38,327 | $148.9K | 19 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Bain Capital Life Sciences Fund, L.P. | 13G amended | 16.76% | 7.7M |
| 14 Aug 2026 | Armistice Capital, LLC | 13G | 7.29% | 3.3M |
| 15 May 2026 | Longitude Capital Partners II, LLC | 13G amended | 8.6% | 3.5M |
| 13 Feb 2026 | Endeavour Medtech Growth II LP | 13G amended | 5.7% | 2.3M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 888.6K | +4.05% | 3.83 |
| 30 Sep 2026 | 854.0K | -9.19% | 2.28 |
| 15 Sep 2026 | 940.4K | +8.16% | 3.73 |
| 31 Aug 2026 | 869.4K | +3.03% | 4.48 |
| 14 Aug 2026 | 843.8K | +2.19% | 2.99 |
| 31 Jul 2026 | 825.8K | -1.97% | 5.05 |
| 15 Jul 2026 | 842.3K | +14.07% | 3.19 |
| 30 Jun 2026 | 738.5K | +20.27% | 3.7 |
Funds that hold it
From each fund's latest Form 13F.
51 funds held it at 30 Jun 2026: 14 added and 12 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,434,560 | $14.6M | 0 |
| Armistice Capital, LLC | 3,328,000 | $5.8M | +3,328,000 |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 1,848,296 | $3.2M | 0 |
| Vanguard Capital Management LLC | 982,034 | $1.7M | -460 |
| Khazanah Nasional Berhad | 566,905 | $980.7K | 0 |
| Evernest Financial Advisors, LLC | 506,000 | $875.4K | +73,490 |
| Advent International, L.P. | 379,794 | $657.0K | -172,583 |
| Essex Investment Management Co. LLC | 362,696 | $627.5K | -521,235 |
| Millennium Management LLC | 236,599 | $409.3K | -46,681 |
| Geode Capital Management, LLC | 228,041 | $394.7K | -19,136 |
Peers
Companies in the same industry.
- Agilent Technologies, Inc. (A): revenue $7.4B, market value $49.3B
- Waters Corp. (WAT): revenue $4.6B, market value $45.4B
- Mettler Toledo International Inc. (MTD): revenue $4.1B, market value $36.3B
- Illumina, Inc. (ILMN): revenue $4.5B, market value $35.7B
- Revvity, Inc. (RVTY): revenue $2.9B, market value $17.5B
- Avantor, Inc. (AVTR): revenue $6.6B, market value $10.9B
- Bio-Rad Laboratories, Inc. (BIO): revenue $2.6B, market value $10.0B
- 10x Genomics, Inc. (TXG): revenue $616.9M, market value $9.1B
- Bruker Corp. (BRKR): revenue $3.5B, market value $8.7B
- Alamar Biosciences, Inc. (ALMR): revenue –, market value $2.1B